Sona Nanotech Inc (SONA) AI Stock Analysis

• Market Cap: C$40.68M
• Dividend Yield: N/A
• Average Volume (3M): 124.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: N/A
• EPS Growth: 10.97%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 113,005,360
• 10 Day Avg. Volume: 87,178
• 30 Day Avg. Volume: 124,263
• PEG Ratio: -2.88
• Price to Book (P/B): -1.80K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -35.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.06
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.38 ▼(-5.75% Downside)
• Action: Upgraded Date: 03/01/26
• Date: Action: Upgraded 03/01/26

The score is driven primarily by very weak financial performance (no reported revenue, ongoing losses, persistent cash burn, and a deteriorated balance sheet with slightly negative equity). Technicals add additional pressure due to a below-average, downtrend setup with negative MACD, while valuation metrics are not supportive given the negative P/E and no dividend yield provided.

Positive Factors

Proprietary gold nanorod technology

The company’s proprietary gold nanorod platform targets diagnostics and assay formats, providing a durable technology moat. A versatile materials platform can support multiple product applications and licensing, enabling long-term revenue pathways if commercialization execution succeeds.

Modest absolute debt with downward trend

Relatively small reported debt and a multi-year downward trend reduce fixed financial obligations and interest exposure, preserving flexibility. This structural decline in leverage helps limit financing drag and supports survivability while commercial progress is pursued.

Cash flow tracks reported losses

FCF aligning with net loss indicates losses aren’t being obscured by non‑cash adjustments or aggressive accounting. This transparency aids forecasting and governance, making cash needs and burn patterns more predictable for long‑term planning and funding decisions.

Negative Factors

No reported revenue (2020–2025)

Zero reported revenue over multiple years shows lack of commercialization traction or persistent product-market fit issues. This structural absence of sales undermines the core business model and implies ongoing dependence on financing rather than operating cash generation.

Persistent and accelerating cash burn

Consistent negative operating cash flow and worsening free cash flow indicate accelerating cash consumption and shrinking runway. Over months, this raises dilution and refinancing risk and constrains ability to invest in commercialization or R&D without external capital.

Negative equity and shrinking asset base

Negative equity and a sharp asset decline signal balance‑sheet deterioration, increasing financial fragility. This reduces borrowing capacity, may limit strategic options, and heightens insolvency risk during extended commercialization timelines absent material financing.

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.

How the Company Makes Money

Sona Nanotech Inc generates revenue primarily through the sale of its proprietary nanomaterials, including gold nanorods, which are utilized in the production of diagnostic assays and other medical technologies. The company monetizes its technology by supplying these nanomaterials to diagnostic test manufacturers, research institutions, and healthcare companies. Additionally, Sona Nanotech may engage in licensing agreements and partnerships with other organizations to expand the application of its technologies and reach new markets. While direct sales of its nanomaterials form the core revenue stream, strategic collaborations and research grants may also contribute to the company's earnings.

Sona Nanotech Inc Financial Statement Overview

Summary

Very weak fundamentals: revenue is 0 across all periods provided, gross profit is consistently negative, and net losses remain large with 2025 worsening vs. 2024. Balance-sheet risk increased as equity turned slightly negative in 2025 and assets fell sharply, while cash flow shows persistent and worsening free-cash-flow burn, implying continued reliance on external funding.

Income Statement

The income statement is very weak: reported revenue is 0 across all annual periods provided (2020–2025), while gross profit is consistently negative, implying ongoing costs without offsetting sales. Losses remain large every year, and the 2025 annual net loss worsened versus 2024 (about -$3.25M vs. -$2.70M), indicating no clear path to profitability based on the disclosed figures. The main strength is that losses have been far smaller than the extreme 2021 loss, but the company is still structurally unprofitable in the most recent year.

Balance Sheet

Leverage is mixed but the balance sheet deteriorated materially in the most recent year. Total debt is relatively modest in absolute dollars (about $308K in 2025), but stockholders’ equity turned slightly negative in 2025 (about -$39K) after being positive in 2024 (about $2.51M), which increases financial risk and reduces flexibility. Total assets also fell sharply from 2024 to 2025 (about $3.75M to $1.33M). A positive is that debt balances have generally trended down since 2020, but the negative equity in the latest period is a significant weakness.

Cash Flow

Cash flow quality is poor due to persistent cash burn. Operating cash flow and free cash flow are negative every year shown, and 2025 free cash flow declined versus 2024 (roughly -$1.96M with a -28.6% growth rate), signaling accelerating burn. A relative positive is that free cash flow roughly tracks net income (loss) in most years (i.e., losses are not being masked by strong cash generation), but the company still requires funding to sustain operations given ongoing negative operating cash flow.

Breakdown	Oct 2025	Jan 2025	Jan 2024	Jan 2023	Jan 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-720.00K	-733.98K	-457.00K	-60.32K	-65.59K
EBITDA	-2.72M	-2.00M	-2.02M	-2.34M	-10.38M
Net Income	-3.25M	-2.70M	-2.50M	-2.36M	-10.77M
Balance Sheet
Total Assets	1.33M	3.75M	2.75M	520.77K	1.52M
Cash, Cash Equivalents and Short-Term Investments	125.95K	1.86M	115.38K	164.42K	1.20M
Total Debt	307.74K	394.67K	527.68K	608.47K	1.34M
Total Liabilities	1.37M	1.24M	1.59M	1.03M	2.75M
Stockholders Equity	-38.78K	2.51M	1.16M	-507.86K	-1.22M
Cash Flow
Free Cash Flow	-1.96M	-1.96M	-1.26M	-1.81M	-3.81M
Operating Cash Flow	-1.96M	-1.96M	-1.26M	-1.81M	-3.81M
Investing Cash Flow	0.00	0.00	14.64K	0.00	0.00
Financing Cash Flow	228.43K	3.70M	1.20M	778.00	4.89M

Sona Nanotech Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.44, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 7.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	50 Neutral	C$60.95M	-35.80	―	―	-21.89%	26.36%
EBM	44 Neutral	C$63.38M	-153.33	―	―	-9.02%	14.29%
MIR	42 Neutral	C$49.12M	-12.07	―	―	-41.70%	-35.42%
SONA	41 Neutral	C$40.68M	-12.29	-2846.90%	―	―	10.97%